| Autor: |
Gershtein ES; V. I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia. biochimia@mtu-net.ru., Isaeva ER; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia., Kushlinsky DN; V. I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia., Korotkova EA; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia., Ermilova VD; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia., Laktionov KP; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia., Adamyan LV; V. I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia. |
| Abstrakt: |
IGF-1, IGF-2, and IGFBP-1,2,3 were assayed in blood serum of patients with malignant ovarian tumors (n=44), borderline ovarian tumors (n=11), and benign ovarian tumors (n=12) as well as in healthy women (n=33). In blood serum of patients with malignant ovarian tumors, the level of IGF-1 was lower and IGFBP-1 was higher than in other groups. In patients with malignant and borderline ovarian tumors, the level of IGFBP-2 was higher than in healthy women and in patients with benign ovarian tumors. There was no correlation between most examined parameters and the clinical and morphological peculiarities of ovarian tumors. The study revealed IGF/IGFBP imbalance in patients with malignant ovarian tumor and showed that IGFBP-2 proved to be a potential diagnostic serological marker w with 90% sensitivity and 90% specificity. |
Full text from SpringerLink